二环己基-(2-甲基苯基)膦 | 172787-73-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 二环己基-(2-甲基苯基)膦
• 英文名称: 2-Hydroxyphytanoyl-CoA
• 英文别名: S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 2-hydroxy-3,7,11,15-tetramethylhexadecanethioate
• CAS: 172787-73-4
• 化学式: C₄₁H₇₄N₇O₁₈P₃S
• 分子量: 1078.1
• InChiKey: WNVFJMYPVBOLKV-YLNUKALLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  70
• 可旋转键数：
  34
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  409
• 氢给体数：
  10
• 氢受体数：
  23

文献信息

• FUNCTIONALIZED CARBOXYLIC ACIDS AND ALCOHOLS BY REVERSE FATTY ACID OXIDATION
  申请人：William Marsh Rice University

  公开号：EP2753689B1

  公开（公告）日：2018-02-14
• Use of branched chain fatty acid amino acid salts and compositions thereof
  申请人：Abraham Sal

  公开号：US20080076721A1

  公开（公告）日：2008-03-27

  The present invention relates to the use of naturally occurring methylated branched chain fatty acids, precursors, or derivatives such as but not limited to 3,7,11,15-tetramethyl-2-Hexadecen-1-ol (phytol), 3,7,11,15-tetramethylhexadec-2-enoic acid (phytenic acid), 3,7,11,15-tetramethylhexadecanoic (phytanic acid) or 2,6,10,14-tetramethylpentadecanoic (pristanic acid) as amino acid salts for cosmetic, dietary supplement, or pharmaceutical compositions, which are useful in increasing the variables associated with physical performance for the regulation of athletic function.
• NOVEL BIOMARKERS OF LIVER CANCER
  申请人：Borlak Jurgen

  公开号：US20130183737A1

  公开（公告）日：2013-07-18

  The invention is based on the surprising finding that proteins regulated by excessive EGFR signalling in the liver may be used as biomarkers in the diagnosis, prognosis and/or monitoring of treatment of diseases, including liver cell dysplasia or hepatocellular carcinoma (HCC), wherein the protein is selected from a first group consisting of Arginase type II, 4931406C07Rik (Ester hydrolase C11orf54 homolog), Akr1c12 protein, Alanyl-tRNA synthetase, Aldo-keto reductase family 1 member C14, Aldo-keto reductase family 1 member C6, Aldolase 3, Alpha glucosidase 2, Beta 5-tubulin, Cai protein (Pdia4), cDNA sequence BC021917 (dihydroxyacetone kinase 2 homolog), Farnesyl diphosphate synthetase, Fatty acid binding protein 5 epidermal, Inosine triphosphatase, Interleukin 25, Kininogen 1, LIM and SH3 protein 1, Major vault protein, Nucb1 protein, Poly(rC) binding protein 2; heterogeneous nuclear ribonucleoprotein X, Psmd11 protein, RIKEN cDNA 2410004H02, Rps12 protein, Sars1 protein, Sorcin, T43799 proteasome protein p45/SUG [imported], Uap1 l1 protein, v-crk sarcoma virus CT10 oncogene homolog, and 170 kDa glucose regulated protein GRP170 precursor, or from a second group consisting of 2-hydroxyphytanoyl-CoA lyase, Branched chain ketoacid dehydrogenase E1 alpha polypeptide; Butyryl Coenzyme A synthetase 1, Dhdh protein, Diacetyl/L-xylulose reductase, Dmgdh protein (Dimethylglycine dehydrogenase, mitochondrial), Enoyl coenzyme A hydratase 1 peroxisomal, Hypothetical protein LOC68347, Lysophospholipase 1, Mitochondrial acyl-CoA thioesterase 1, PREDICTED: agmatine ureohydrolase (agmatinase), RIKEN cDNA 1810013B01 (abhydrolase domain containing 14b), and Serpinb1a protein. Based on this finding novel biomarkers and molecules binding to said biomarkers, compositions and a kit, as well as methods for the diagnosis, prognosis and/or monitoring of treatment of dysplasia and cancer patients, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC) patients are provided according to the invention.
• US20140273110A1
  申请人：——

  公开号：US20140273110A1

  公开（公告）日：2014-09-18
• US9994881B2
  申请人：——

  公开号：US9994881B2

  公开（公告）日：2018-06-12